A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (G-LUCAS)
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type, Metastatic Colorectal Cancer
Sponsor: Austrian Breast & Colorectal Cancer Study Group
Terminated
Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.
Other terminated trials from Austrian Breast & Colorectal Cancer Study Group
More terminations from Austrian Breast & Colorectal Cancer Study Group
Other Colorectal Cancer trials with similar outcome
Listed as NCT01523639, this PHASE2 trial focuses on Colorectal Cancer and Steatohepatitis and remains terminated or withdrawn. Sponsored by Austrian Breast & Colorectal Cancer Study Group, it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jan 2019 — Nov 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE2
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Austrian Breast & Colorectal Cancer Study Group
- Merck Gesellschaft mbH, Austria
For direct contact, visit the study record on ClinicalTrials.gov .